FDA Approves Hetlioz for the Treatment of Non-24-Hour Sleep-Wake Disorder
Vanda Pharmaceuticals receives approval from FDA for Hetlioz for the treatment of Non-24.
Vanda Pharmaceuticals reported that FDA has approved Hetlioz (tasimelteon) 20 mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). Hetlioz is the first FDA approved medication for Non-24.
Non-24 is a chronic, circadian rhythm disorder resulting from the misalignment of the endogenous master body clock to the 24-hour day, disrupting the sleep-wake cycle. Vanda anticipates making Hetlioz commercially available in the second quarter of 2014.
Source: Vanda Pharmaceuticals
Recent Videos
Related Content
